Immediate release fixed dose combination product [Regulatives / Guidelines]

posted by Dr_Dan  – Germany, 2020-03-11 11:47 (836 d 03:41 ago) – Posting: # 21240
Views: 3,902

Hello ping4santosh,
Even if you aim at substitution indication (improvement of patient's compliance) presenting co-prescription data and therapeutic guidelines recommending the co-administration will not suffice as long as you are unable to present clinical data demonstrating safety and efficacy of the respective combination. IMHO it will be hard to identify a new FDC which can be approved without a phase III study (at least in western Europe).

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
22,166 posts in 4,645 threads, 1,572 registered users;
online 4 (0 registered, 4 guests [including 2 identified bots]).
Forum time: Saturday 16:29 CEST (Europe/Vienna)

Absolute certainty is a privilege of uneducated minds  and fanatics.
It is, for scientific folk, an unattainable ideal.    Cassius J. Keyser

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5